BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on Lynparza® (olaparib): risk of medication errors due to new dosage forms

Active substance: olaparib

Lynparza® capsules and Lynparza® tablets must neither be substituted 1:1 nor on a milligramme-to-milligramme basis.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 552KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK